Search
Kairos Pharma Ltd
KAPAAdd to Watchlist
0.482USD
-0.010-2.05%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
10.32MMarket Cap
LossP/E TTM
More Details of Kairos Pharma Ltd Company
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. It is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.
Kairos Pharma Ltd Info
Ticker SymbolKAPA
Company nameKairos Pharma Ltd
IPO dateSep 16, 2024
CEOYu (John S)
Number of employees1
Security typeOrdinary Share
Fiscal year-endSep 16
Address2355 Westwood Blvd. #139
CityLOS ANGELES
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code90064
Phone18184045541
Websitehttps://kairospharma.com
Ticker SymbolKAPA
IPO dateSep 16, 2024
CEOYu (John S)
Company Executives of Kairos Pharma Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. John S. Yu, M.D.
Dr. John S. Yu, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
5.35M
-3.47%
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Independent Director
Independent Director
5.57K
-422.25%
Dr. Rahul Singhvi
Dr. Rahul Singhvi
Independent Director
Independent Director
5.57K
-783.53%
Dr. Neil Bhowmick, Ph.D.
Dr. Neil Bhowmick, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Ramachandran Murali, Ph.D.
Dr. Ramachandran Murali, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Mr. Douglas W. (Doug) Samuelson, CPA
Mr. Douglas W. (Doug) Samuelson, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Hyun W. Bae, M.D.
Dr. Hyun W. Bae, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. John S. Yu, M.D.
Dr. John S. Yu, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
5.35M
-3.47%
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Independent Director
Independent Director
5.57K
-422.25%
Dr. Rahul Singhvi
Dr. Rahul Singhvi
Independent Director
Independent Director
5.57K
-783.53%
Dr. Neil Bhowmick, Ph.D.
Dr. Neil Bhowmick, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Ramachandran Murali, Ph.D.
Dr. Ramachandran Murali, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Mr. Douglas W. (Doug) Samuelson, CPA
Mr. Douglas W. (Doug) Samuelson, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Yu (John S)
24.97%
Technomedics Management and Systems, Inc
5.32%
Bhowmick (Neil Ph.D.)
5.30%
Citadel Advisors LLC
1.50%
Vanguard Capital Management, LLC
1.08%
Other
61.82%
Shareholders
Shareholders
Proportion
Yu (John S)
24.97%
Technomedics Management and Systems, Inc
5.32%
Bhowmick (Neil Ph.D.)
5.30%
Citadel Advisors LLC
1.50%
Vanguard Capital Management, LLC
1.08%
Other
61.82%
Shareholder Types
Shareholders
Proportion
Individual Investor
31.88%
Corporation
5.32%
Hedge Fund
2.03%
Investment Advisor
1.96%
Investment Advisor/Hedge Fund
0.45%
Venture Capital
0.23%
Research Firm
0.10%
Other
58.04%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
24
1.15M
5.38%
-1.12M
2025Q4
21
415.57K
2.00%
-1.81M
2025Q3
17
350.58K
1.69%
-1.62M
2025Q2
19
9.54M
54.94%
+1.17M
2025Q1
19
10.48M
74.82%
+2.27M
2024Q4
13
9.19M
70.90%
+3.62M
2024Q3
9
8.91M
68.86%
+8.91M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Yu (John S)
5.53M
26.57%
+190.84K
+3.57%
Oct 08, 2025
Technomedics Management and Systems, Inc
1.17M
5.64%
--
--
Jul 28, 2025
Bhowmick (Neil Ph.D.)
1.30M
6.25%
+171.76K
+15.20%
Oct 08, 2025
Citadel Advisors LLC
321.74K
1.55%
+321.74K
--
Dec 31, 2025
Murali (Ramachandran Ph.D.)
290.20K
1.39%
+152.67K
+111.01%
Oct 08, 2025
Samuelson (Doug)
257.56K
1.24%
+152.67K
+145.56%
Oct 08, 2025
Two Sigma Investments, LP
109.15K
0.52%
+38.47K
+54.42%
Dec 31, 2025
Geode Capital Management, L.L.C.
72.83K
0.35%
+7.03K
+10.69%
Dec 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
